Non-Alcoholic Steatohepatitis Biomarkers Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Non-Alcoholic Steatohepatitis Biomarkers Market Size From 2025 to 2034?
In recent times, there has been remarkable growth in the market size of non-alcoholic steatohepatitis biomarkers. The market, which was valued at $1.36 billion in 2024, is predicted to reach $1.68 billion in 2025, reflecting a compound annual growth rate (CAGR) of 23.9%. Factors such as diabetes and metabolic syndrome, awareness and screening initiatives, drawbacks of liver biopsy, regulatory endorsements, a move towards personalized healthcare, and clinical trials focussed on NASH have contributed to the growth observed in the historic timeframe.
In the upcoming years, substantial expansion is anticipated in the non-alcoholic steatohepatitis biomarkers market, which is predicted to surge to $3.81 billion in 2029, with a compound annual growth rate (CAGR) of 22.6%. Factors contributing to the projected growth extend from the advent of innovative therapies and expansion of precision medicine approaches to patient advocacy initiatives, incorporation of multi-omics data and improved patient involvement. The forecast period also sees trends like telemedicine and remote monitoring, groundbreaking diagnostic platforms, international research collaborations, technological advancements in the field of biomarker discovery and the utilization of artificial intelligence (AI) along with the inclusion of imaging biomarkers.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis Biomarkers Market?
The rise in liver cancer cases is anticipated to drive the expansion of the non-alcoholic steatohepatitis biomarkers market. Liver cancer involves the growth of malignant tumors in the liver, which can originate in the liver itself (primary liver cancer) or could be a result of metastasis from other parts of the body (secondary or metastatic liver cancer). Biomarkers for non-alcoholic steatohepatitis (NASH) are employed in the early diagnosis, tracking of disease development, and assessment of treatment response in liver cancer. They provide essential prognostic information and can aid in minimizing the necessity for invasive procedures. For example, in 2022, the World Cancer Research Fund, a non-profit organization based in the UK, reported approximately 866,136 fresh cases of liver cancer around the globe, making liver cancer the 6th most prevalent cancer worldwide. Consequently, the surge in liver cancer instances is driving the expansion of the non-alcoholic steatohepatitis biomarkers market.
Which Primary Segments of the Non-Alcoholic Steatohepatitis Biomarkers Market Are Driving Growth and Industry Transformations?
The non-alcoholic steatohepatitis biomarkersmarket covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis Biomarkers Market?# Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Technological Trends Are Reshaping the Non-Alcoholic Steatohepatitis Biomarkers Industry Dynamics?
One significant trend in the non-alcoholic steatohepatitis biomarkers market is the role of progressive technologies. Prevalent organizations in this market are leveraging innovation to reinforce their market stance. For example, in October 2022, France’s late-stage biopharmaceutical firm, GENFIT partnered with LabCorp, an American life sciences enterprise, for an exclusive five-year license of GENFIT’s NIS4 technology. This technology was created to single out patients with non-alcoholic steatohepatitis-at-risk (NASH), specifically those with significant or advanced fibrosis (F > 2) otherwise known as at-risk NASH. As part of this agreement, LabCorp will create and market a blood-based molecular diagnostic test using NIS4 technology across the United States and Canada, greatly extending its availability to healthcare professionals.
View the full report here:
What Parameters Are Used to Define the Non-Alcoholic Steatohepatitis Biomarkers Market?
Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9002
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
